Harvard Bioscience Reports $20.8M Revenue in Q1 2026, Net Loss Improves to $3.4M

Harvard Bioscience, Inc. reported a revenue of $20.8 million for the first quarter of 2026, a decrease of 4.7% from $21.8 million in the same period of 2025. The decline in revenue was primarily attributed to reduced sales from academic research institutions in the Americas and distributors in the Asia Pacific region. Despite the drop in revenue, the company's gross profit remained stable at $12.2 million, resulting in a gross margin increase to 59.0%, up from 56.0% in the prior year, largely due to a favorable product mix and cost reductions implemented in the previous year.

The company recorded a net loss of $3.4 million for the first quarter of 2026, a significant improvement compared to a net loss of $50.3 million in the same quarter of 2025, which included a substantial goodwill impairment charge of $48 million. Operating expenses for the latest quarter totaled $13.4 million, down from $61.9 million a year earlier, reflecting the absence of the goodwill impairment and a reduction in general and administrative expenses. Interest expenses increased to $1.7 million, up from $0.9 million, primarily due to higher interest rates associated with the company's refinancing efforts.

In terms of strategic developments, Harvard Bioscience initiated "Project Viking," a comprehensive plan aimed at consolidating its manufacturing operations to enhance efficiency and support long-term growth. This initiative includes the closure of its manufacturing facility in Holliston, Massachusetts, with production being transitioned to its hub in Minneapolis, Minnesota, and other facilities in Europe. The company anticipates achieving approximately $3 million in cost savings in 2027 and $4 million annually starting in 2028 as a result of these changes.

Operationally, the company reported a slight increase in its employee headcount, with 4,511 shares of common stock outstanding as of March 31, 2026, compared to 4,472 shares at the end of 2025. The company also experienced a decrease in contract liabilities, which rose to $3.8 million from $3.6 million, primarily due to the timing of payments under service contracts. Harvard Bioscience continues to focus on expanding its market presence, particularly in the life sciences sector, while navigating challenges such as global economic conditions and trade tariffs.

Looking ahead, Harvard Bioscience expressed optimism about its ability to continue as a going concern, having alleviated initial doubts regarding its financial stability. The company is committed to maintaining compliance with its financial covenants under the 2025 Loan Agreement, which includes a minimum liquidity requirement of $3 million and a minimum adjusted EBITDA requirement of $6 million. The management remains focused on aligning its operations with strategic growth objectives while adapting to market conditions.